Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 17/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5461100 | 0.89 | MAOA (0.44) | MAOACYP3A4CYP2D6MAOBKCNH2 | |
| SCHEMBL5468290 | 0.85 | CYP3A4 (0.61) | MAOACYP3A4CYP2D6MAOBKCNH2 | |
| SCHEMBL6422776 | 0.85 | MAOA (0.41) | MAOACYP3A4CYP2D6MAOB | |
| SCHEMBL6336919 | 0.85 | MAOA (0.41) | MAOACYP3A4CYP2D6MAOB | |
| SCHEMBL6336922 | 0.85 | MAOA (0.41) | MAOACYP3A4CYP2D6MAOB | |
| SCHEMBL6336924 | 0.85 | MAOA (0.41) | MAOACYP3A4CYP2D6MAOB | |
| SCHEMBL6337007 | 0.84 | MAOA (0.53) | MAOAMAOB | |
| SCHEMBL5453269 | 0.83 | CYP3A4 (0.63) | MAOACYP3A4CYP2D6MAOBKCNH2 | |
| SCHEMBL5461284 | 0.80 | MAOA (0.62) | MAOACYP3A4CYP2D6MAOBKCNH2 | |
| SCHEMBL5462815 | 0.78 | MAOA (0.62) | MAOACYP3A4CYP2D6MAOBKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070293493-A1 | OXAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2007-12-20 | — | — | US | claimed |
| EP-1646630-A1 | OXAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF | Merck & Co., Inc. (US) | 2006-04-19 | — | — | EP | claimed |
| WO-2005005422-A1 | OXAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF | MERCK & CO., INC. (US) | 2005-01-20 | — | — | WO | claimed |
| US-20070293493-A1 | OXAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2007-12-20 | — | — | US | disclosed |
| EP-1646630-A1 | OXAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF | Merck & Co., Inc. (US) | 2006-04-19 | — | — | EP | disclosed |
| WO-2005005422-A1 | OXAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF | MERCK & CO., INC. (US) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293493-A1 | OXAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF | OXA1L, RORC, IL17A | MAOA 3244/4885CYP3A4 154/4885CYP2D6 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.